Skip to main content

Advertisement

SpringerLink
Log in

The prognostic role of CD133 expression in patients with osteosarcoma

  • Original Article
  • Published:
Clinical and Experimental Medicine Aims and scope Submit manuscript

Abstract

Osteosarcoma (OS), a malignant bone tumor, mainly occurs in adolescents. Cluster of differentiation 133 (CD133) is one of the most common tumor stem cell biomarkers. The prognostic significance of CD133 in OS has been reported, while the conclusions of these study were inconsistent. This study was conducted to investigate the association between CD133 expression and OS. We performed a search using several database including NCBI PubMed, Springer, CNKI, Web of Science and Wanfang for relevant papers about the prognostic value of CD133 on OS published before October 19, 2019. Pooled odds ratio (OR) and 95% CI were used to evaluate the outcomes. Seven reports including 498 OS patients were used for evaluating the association between CD133 positive expression and OS clinicopathological features. CD133 positive expression was not related to the age, gender, tumor size, tumor location and pathological type of OS. The expression of CD133 was significantly associated with high ennecking stage of OS (OR 9.67, 95% CI 5.56–16.80, P < 0.05) and OS local recurrence (OR 3.02, 95% CI 1.84–4.94, P < 0.05). In addition, the expressions of CD133 predict metastasis (OR 7.64, 95% CI 4.93–11.85, P < 0.05). Moreover, this study indicated that CD133 expression was correlated to lower 5-year overall survival in OS with the pooled OR of 5.85 (95% CI 3.30–10.37, P < 0.05). Our reported shown that positive expression of CD133 is significantly correlated with ennecking stage, local recurrence, metastasis and low 5-year overall survival rate of OS patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Abbreviations

CD133:

Cluster of differentiation 133

OS:

Osteosarcoma

CNKI:

China National Knowledge Internet database

CBM:

Chinese Biological Medical Database

NOS:

Newcastle–Ottawa Quality Assessment Scale

OR:

Odds ratio

95% CI:

95% confidence interval

References

  1. Bertucci F, Araujo J, Giovannini M. Pancreatic metastasis from osteosarcoma and Ewing sarcoma: literature review. Scand J Gastroenterol. 2013;48:4–8.

    Article  Google Scholar 

  2. Kong C, Hansen MF. Biomarkers in osteosarcoma. Expert Opin Med Diagn. 2009;3:13–23.

    Article  CAS  Google Scholar 

  3. Ottaviani G, Jaffe N. The etiology of osteosarcoma. Cancer Treat Res. 2009;152:15–32.

    Article  Google Scholar 

  4. Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20:776–90.

    Article  Google Scholar 

  5. Bao Y, Chen B, Wu Q, et al. Overexpression of miR-664 is associated with enhanced osteosarcoma cell migration and invasion ability via targeting SOX7. Clin Exp Med. 2017;17:51–8.

    Article  CAS  Google Scholar 

  6. Ta HT, Dass CR, Choong PF, Dunstan DE. Osteosarcoma treatment: state of the art. Cancer Metastasis Rev. 2009;28:247–63.

    Article  Google Scholar 

  7. Wang X, Ning Y, Yang L, et al. Diagnostic value of circulating microRNAs for osteosarcoma in Asian populations: a meta-analysis. Clin Exp Med. 2017;17:175–83.

    Article  CAS  Google Scholar 

  8. Li YJ, Dai YL, Zhang WB, Li SJ, Tu CQ. Clinicopathological and prognostic significance of chemokine receptor CXCR4 in patients with bone and soft tissue sarcoma: a meta-analysis. Clin Exp Med. 2017;17:59–69.

    Article  CAS  Google Scholar 

  9. Han G, Wang Y, Bi W, Jia J, Wang W, Xu M. Effects of vascular endothelial growth factor expression on pathological characteristics and prognosis of osteosarcoma. Clin Exp Med. 2016;16:577–84.

    Article  CAS  Google Scholar 

  10. Gorlick R. Osteosarcoma: clinical practice and the expanding role of biology. J Musculoskelet Neuronal Interact. 2002;2:549–51.

    CAS  PubMed  Google Scholar 

  11. Durnali A, Alkis N, Cangur S, et al. Prognostic factors for teenage and adult patients with high-grade osteosarcoma: an analysis of 240 patients. Med Oncol. 2013;30:624.

    Article  Google Scholar 

  12. Zhou J, Liu T, Wang W. Prognostic significance of matrix metalloproteinase 9 expression in osteosarcoma: a meta-analysis of 16 studies. Medicine (Baltimore). 2018;97:e13051.

    Article  Google Scholar 

  13. Zhou J, Xiao X, Wang W, Luo Y. Association between PTEN and clinical-pathological features of osteosarcoma. Biosci Rep. 2019;39:BSR20190954.

    Article  CAS  Google Scholar 

  14. Zhou J, Wang W, Yan Q, Luo Y. Expression of HER-2 in surgical specimen and biopsy as a biomarker of metastasis in patients with osteosarcoma: a meta-analysis. Transl Cancer Res. 2019;8:1129–36.

    Article  Google Scholar 

  15. George W, Beverley JS, Dianne O, et al. The Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2000. http://www.evidencebasedpublichealth.de/download/Newcastle_Ottowa_Scale_Pope_Bruce.pdf.

  16. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.

    Article  Google Scholar 

  17. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.

    CAS  PubMed  Google Scholar 

  18. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.

    Article  CAS  Google Scholar 

  19. Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.

    Article  CAS  Google Scholar 

  20. Xie Y, Huang J, Wu M, Zhou Y. Expression of CD133 protein in osteosarcoma and its relationship with the clinicopathological features and prognosis. J Cancer Res Ther. 2018;14:892–5.

    Article  CAS  Google Scholar 

  21. Bao Z, Cheng Z, Chai D. The expressions of CD133, ALDH1, and vasculogenic mimicry in osteosarcoma and their clinical significance. Int J Clin Exp Pathol. 2018;11:3656–63.

    PubMed  PubMed Central  Google Scholar 

  22. Hong F, Yuan G, Zhang H, et al. Expression of microtubule instability protein and CD133 in osteosarcoma and its clinical significance. Chin J Exp Surg. 2017;3:516–8.

    Google Scholar 

  23. Qian T, Yu L, Zhang C, Zhou J. Increased immunohistochemical expression and angiogenesis of CD133 and ALDH1 in osteosarcoma. Chin J Histochem Cytochem. 2016;25:143–7.

    CAS  Google Scholar 

  24. Lin J, Lin J, Wu C, et al. Expression and clinical pathology of osteosarcoma CD133 CD117 Ki-67 correlation between factors and risk. Chin J Clin Oncol. 2014;41:305–10.

    CAS  Google Scholar 

  25. He A, Qi W, Huang Y, et al. CD133 expression predicts lung metastasis and poor prognosis in osteosarcoma patients: a clinical and experimental study. Exp Ther Med. 2012;4:435–41.

    Article  CAS  Google Scholar 

  26. He A, Qi W, Tang L, et al. Expression of CD133 and CD44 in osteosarcoma and its clinical significance. Cancer Prev Res. 2012;39:1328–32.

    CAS  Google Scholar 

  27. Picci P, Mercuri M, Ferrari S, et al. Survival in high-grade osteosarcoma: improvement over 21 years at a single institution. Ann Oncol. 2010;21:1366–73.

    Article  CAS  Google Scholar 

  28. Giebel B, Corbeil D, Beckmann J, et al. Segregation of lipid raft markers including CD133 in polarized human hematopoietic stem and progenitor cells. Blood. 2004;104:2332–8.

    Article  CAS  Google Scholar 

  29. Bruno S, Bussolati B, Grange C, et al. CD133+ renal progenitor cells contribute to tumor angiogenesis. Am J Pathol. 2006;169:2223–35.

    Article  CAS  Google Scholar 

  30. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007;445:106–10.

    Article  CAS  Google Scholar 

  31. Tirino V, Desiderio V, D'Aquino R, et al. Detection and characterization of CD133+ cancer stem cells in human solid tumours. PLoS ONE. 2008;3:e3469.

    Article  Google Scholar 

  32. Xiao D, Wang Y, Xu B. Introduction and inspiration of meta-analysis. Med Philos. 1998;19:179–182.

    Google Scholar 

Download references

Funding

This work was supported by the Mittal Innovation Project of Central South University (Grant No. GCX20190879Y), the Fundamental Research Funds for the Central Universities of Central South University (Grant No. 2018zzts930), the Central South University Sports Medicine Scholarship, the National College Students’ Innovation and Entrepreneurship Training Program (Grant No. 201710422116).

Author information

Authors and Affiliations

  1. Department of Spine Surgery, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China

    Nuo Xu & Yijun Kang

  2. Department of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China

    Wanchun Wang & Jian Zhou

Authors
  1. Nuo Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yijun Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wanchun Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jian Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

NX, JZ, WW: Data curation. NX, YK, JZ: Formal analysis. NX, JZ: Funding acquisition. NX, JZ, WW: Investigation. NX, JZ, YK, WW: Methodology. JZ, YK, WW: Writing—original draft. JZ, WW: Writing—review & editing.

Corresponding authors

Correspondence to Yijun Kang, Wanchun Wang or Jian Zhou.

Ethics declarations

Conflict of interest

The authors wish to declare that there is no known conflict of interests associated with this publication.

Informed consent

All studies included in this study got informed consent from each study participant and that each study was approved by ethics committee or institutional review board.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

S1 Table. Qualitative assessment of included study. (DOCX 14 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Xu, N., Kang, Y., Wang, W. et al. The prognostic role of CD133 expression in patients with osteosarcoma. Clin Exp Med 20, 261–267 (2020). https://doi.org/10.1007/s10238-020-00607-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10238-020-00607-6

Keywords

Search

Navigation